Drs I H FAHAL, P S WILLIAMS, R E CLARK, and G M BELL (Royal Liverpool University Hospital, Liverpool L7 8XP) write: Thrombotic thrombocytopenic purpura is usually rapidly progressive with 75% mortality in three months if untreated.' Plasma exchange has improved the prognosis, though the mortality is still 30%. Haematological and renal abnormalities have been noted in patients receiving rifampicin but the syndrome of thrombotic thrombocytopenic purpura has not. We report a case of thrombotic thrombocytopenic purpura in a patient taking rifampicin.
A 57 year old white man with renal tuberculosis started treatment with rifampicin 450 mg, isoniazid 300 mg, and ethambutol 1200 mg daily. Three weeks later he complained of nausea, vomiting, and malaise. On examination he was confused, anaemic, and jaundiced. His pulse was regular at 100 beats/min, and his blood pressure was 80/50 mm Hg. His liver was palpable 1 cm below the costal margin, but there was no splenomegaly or lymphadenopathy. Rectal examination showed melaena.
His serum concentration of urea was 36-1 mmol/l, creatinine 402 wtmol/l, haemoglobin 100 g/l, and platelets 13 x10 '/1. His 
